Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Orano Med LLC · Neuroendocrine Tumors
Phase 2
Active, not recruiting
69
2026-04
Industry sponsor intelligence
Orano Med LLCClinical Pipeline.
Lead-sponsor view of Orano Med LLC's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 51
Pipeline overview
Programs by phase and activity.
Velocity
Orano Med LLC trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Octreotide → | 2 | 1 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Orano Med LLC studies.
This page groups studies where Orano Med LLC is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first